Benzalkonium Chloride Induced Bronchoconstriction in Patients with Stable Bronchial Asthma

Byoung Hoon Lee, M.D. and Sang-Hoon Kim, M.D.

Department of Internal Medicine, Eulji General Hospital, Eulji University School of Medicine, Seoul, Korea

Background: Although benzalkonium chloride (BAC)-induced bronchoconstriction occurs in patients with bronchial asthma, BAC-containing nebulizer solutions are still being used in daily practice in Korea. The aim of this study was to evaluate the effects of inhaled aqueous solutions containing BAC.

Methods: Thirty subjects with bronchial asthma and 10 normal controls inhaled up to three 600 μg nebulized doses of BAC using a jet nebulizer. FEV₁ (forced expiratory volume at one second) was measured 15 minutes after each dose. Inhalations were repeated every 20 minutes until FEV₁ decreased by 15% or more (defined as BAC-induced bronchoconstriction) or the 3 doses were administered.

Results: The percent fall in FEV₁ in response to BAC inhalation was significantly higher in asthmatics than in normal subjects (p<0.05). BAC administration in subjects with asthma reached a plateau (maximal effect). BAC-induced bronchoconstriction was found in 6 asthmatics (20%), with two responders after the 2nd inhalation and 4 after the 3rd inhalation. The percent fall in FEV₁ in response to the 1st inhalation of BAC was significantly higher in asthmatics with higher bronchial hyperresponsiveness (BHR) than in those with lower BHR.

Conclusions: This study suggests that the available multi-dose nebulized solution is generally safe. However, significant bronchoconstriction can occur at a relatively low BAC dose in asthmatics with severe airway responsiveness.

Key Words: Asthma, Benzalkonium chloride, Bronchoconstriction

INTRODUCTION

Benzalkonium chloride (BAC) is one of several quaternary ammonium compounds used in pharmaceuticals as antiseptics and disinfectants. It is also the most common preservative in nebulizer solutions. BAC has been associated with unintended bronchoconstriction after use of aerosolized asthma medications and after occupational exposure. For example, isotonic ipratropium bromide inhalation solution containing 0.25 mg/mL BAC caused significant bronchoconstriction in patients with asthma (20% drop of FEV₁ in 6 of 22 subjects), and BAC-induced bronchoconstriction has been documented in successive studies. BAC in nebulizer solutions may also lead to respiratory arrest. These reports provoked a worldwide call for the withdrawal of BAC from nebulizer solutions. Although most BAC-containing nebulizer solutions disappeared from clinical use, 0.5% albuterol (salbutamol) non-sterile solution, which contains 50 μg of BAC per 2.5 mg of albuterol, is still frequently prescribed in everyday practice for the treatment of bronchial asthma in Korea.

We therefore evaluated the effect of BAC inhalation in patients with stable bronchial asthma to assess the safety of BAC-containing nebulizer solutions.
MATERIALS AND METHODS

Subjects
Among patients with stable bronchial asthma who had visited our outpatient clinic, 30 patients with a baseline FEV₁ of 65% or greater of the predicted value were selected for this study. Bronchial asthma was diagnosed by the presence of symptoms compatible of bronchial asthma and positive results in a methacholine bronchial provocation test (MBPT) or bronchodilator response (BDR). MBPT was considered positive when the methacholine concentration needed to decrease post-provocation FEV₁ by more than 20% of the baseline value (methacholine PC₂₀; FEV₁) was less than 25 mg/mL, and BDR was deemed positive when the post-bronchodilator increase of FEV₁ was more than 12% of the pre-bronchodilator value. Stable bronchial asthma was defined as asthma with no asthmatic attack resulting in a hospital visit during two recent, consecutive months; no change of medication due to exacerbation: and FEV₁ changes of less than 10% of the patient’s best FEV₁.

Subjects with a history of life-threatening asthma or anaphylaxis were excluded from the study. Other reasons for exclusion were an emergency department visit, hospitalization for asthma within the previous 3 months, a report of use of oral corticosteroids within the previous 3 months, or a respiratory tract infection during or within 6 weeks before the study. Before the study began, subjects had abstained from short-acting β₂-adrenergic bronchodilators for at least 6 hours, long-acting β₂-adrenergic bronchodilators for a minimum of 48 hours, short-acting antihistamines for 4 days, and leukotriene modifiers for 48 hours. The control group consisted of 10 adult subjects with normal spirometry and negative MBPT.

This study was approved by the Institutional Review Board of Eulji Hospital.

Study design
Before the provocation study, spirometry was performed to ensure that FEV₁ was 65% or greater of the predicted value and within ±10% of the value measured in the previous study. The bronchial provocation test was performed with BAC following a method modified from that used by Asmus and colleagues. The subject inhaled 3 mL of 0.9% NaCl solution and then 3 mL of 0.9% NaCl solution containing 600 μg of BAC (Sigma, St. Louis, MO, U.S.A.). The solutions were prepared using aseptic techniques and stored at 2°C in an Eppendorf tube. They were allowed to warm to room temperature immediately prior to use. Each 3 mL dose was inhaled using normal tidal breathing through a DeVilbiss 646 nebulizer (DeVilbiss Co., Somerset, PA, U.S.A.). Vmax22® spirometry (SensorMedics, Yorba Linda, CA, U.S.A.) was performed 15 minutes after the inhalation of each dose began.

The provocation was repeated every 20 minutes until FEV₁ decreased by at least 15% or until a maximum of three doses had been administered. BAC-induced bronchoconstriction was defined as a decrease of 15% or more in FEV₁ after each BAC inhalation. To compare differences in BAC-induced bronchoconstriction according to airway responsiveness, asthmatics with PC₂₀ less than 4.0 mg/mL were also analyzed as a separate subgroup.

The subjects were given 100 μg of albuterol (Ventolin® evohaler, GlaxoSmithKlein, Middlesex, U.K.) with a metered-dose inhaler to reverse bronchoconstriction if it occurred or on request. The albuterol dose was repeated, if necessary, 20 minutes later.

Statistics
Basal characteristics between the asthmatic and control groups were compared by a Student’s t-test for continuous variables and a chi-square test for categorical variables. BAC-induced decreases in FEV₁ and differences in bronchoconstriction between groups were divided by means of airway sensitivity and compared using a paired t-test and a Mann-Whitney test, respectively. We used the SPSS software package (SPSS 11.0.0, SPSS Inc., Chicago, IL, U.S.A.) and a p value of <0.05 was considered statistically significant.

RESULTS
There were no significant differences in age, sex, FEV₁ % predicted value, or smoking status between asthmatic patients and control subjects (Table 1). A total of three BAC inhalations, for a cumulative dose of 1,800 μg, was given to 30 patients and 10 normal control participants: among the 30 patients, two did not inhale the 3rd BAC solution because their decreased FEV₁ exceeded 15% of the baseline value.

The mean FEV₁ values at baseline, 1st, 2nd and 3rd inhalation were 2.36 L ±0.74 L, 2.26 L ±0.64 L, 2.18 L ±0.63 L and 2.17 L ±0.65 L in asthmatics, and 3.32 L ±0.91 L, 3.33 L ±0.82 L, 3.33 L ±0.90 L and 3.34 L ±0.85 L in the control group, respectively. In asthmatics, the mean percent fall in FEV₁ after each inhalation was 2.69%, 5.36%, and 5.30%, respectively. FEV₁ after the 1st and the 2nd inhalations decreased significantly from the previous value (p<0.001, p<0.001), but there was no difference between FEV₁ after the 2nd and 3rd inhalation (p=0.973) (Figure 1). There were no significant changes in FEV₁ in the control group.

BAC-induced bronchoconstriction (a decrease of FEV₁ by 15% or more) was found in 6 patients (2/30, 20%), with 2 responders after the 2nd inhalation and 4 after the 3rd inhalation. Patients with BAC-induced bronchoconstriction complained of
Table 1. Subject characteristics

|                      | Asthmatics (n=30) | Normal controls (n=10) |
|----------------------|-------------------|------------------------|
| Age (yr)             | 45.9±15.7         | 42.0±21.4              |
| Male, n (%)          | 20 (67)           | 7 (70)                 |
| Never smoker, n (%)  | 14 (46)           | 4 (40)                 |
| FVC (L)              | 3.6±0.9           | 4.1±1.1                |
| FVC (% of predicted) | 94±16             | 103±8                  |
| FEV1 (L)             | 2.4±0.7           | 3.3±0.9                |
| FEV1 (% of predicted)| 74±19             | 87±11                  |
| Methacholine PC20, (n=10, mg/mL) | 5.95 (0.77-20.0)* | Not done               |
| % change of post bronchodilator FEV1 (n=20, %) | 16.5 (12-20)* | Not done               |

Data are expressed as means±SD unless otherwise noted. There were no significant differences between the two groups. *: median (range).

Figure 1. Course of mean % change in FEV1 after inhaling BAC in asthmatics and controls. Changes of FEV1 after BAC inhalation were cumulative up to 1200 μg and reached a plateau. There was no significant bronchoconstriction in the control group.

- : p<0.01, compared with baseline value.
* : p<0.01, compared with 600 μg BAC

Figure 2. % change of FEV1 after inhaling BAC according to the sensitivity of airway responsiveness (PC20 less than 4.0 mg/mL or not). A significant change in FEV1 between the two groups was observed only after the 1st inhalation.

*: p<0.05.

DISCUSSION

BAC-induced decreases in FEV1 were cumulative up to 1,200 μg and the reached a plateau, with significant bronchoconstriction (decrease of FEV1 ≥15%) occurring in 6 of the 30 patients with stable bronchial asthma (6/30, 20%). BAC-induced bronchoconstriction was initially more severe in patients with more sensitive airway responsiveness, but this trend disappeared with additional BAC doses. BAC-induced bronchoconstriction was easily reversed with a short-acting β2-agonist.

BAC-induced bronchoconstriction is cumulative, prolonged, and determined by basal airway responsiveness5,6). Zhang and colleagues reported that the range of BAC PC20 FEV1 was 0.03 to 5.5 μmol (1 μmol is equivalent to 354 μg of BAC). When they repeatedly doubled the BAC concentration from 0.044 to 5.64 μmol, bronchoconstrictions (≥10% fall in FEV1) developed in 25 of 28 subjects during a BAC inhalation challenge, and 17 of 28 subjects showed at least a 20% decrease of FEV1. The dose–response to BAC was steep and did not appear to plateau. There was also a significant correlation between histamine PC20 FEV1 and BAC PC20 FEV15,6).

The results of Asmus and colleagues confirmed the observations of previous investigators: 10 (55%) of 18 subjects showed at least a 20% decrease in FEV1. They increased the inhaled dose of BAC from 600 to 2,400 μg with respective inhalations of 600 μg of BAC at 20-minute intervals. This cumulative manner of BAC inhalation more closely approximates the clinical situation than the method employed in the
study of Zhang and colleagues. In the latter study, the authors intended to calculate BAC PC_{20} FEV_1, and the dose of BAC was doubled as in the dosing method of the methacholine provocation test.

There are some notable differences between the results of our study and previous results. First, we found that bronchoconstriction due to BAC inhalation reached a plateau after a cumulative BAC dose of 1,200 μg. Whereas asthmatics with moderate to severe bronchial hyperresponsiveness were selected, our study included patients with mild bronchial hyperresponsiveness, who may be less sensitive to BAC inhalation, allowing dosing to reach a plateau. Second, the difference in BAC-induced bronchoconstriction was not maintained with additional doses in patients more severe airway responsiveness (PC_{20} less than 4.0 mg/mL). A significant difference was observed only at the 1st inhalation of BAC 600 μg, with bronchoconstriction reaching a plateau earlier in these patients (Figure 2). Further studies are needed to clarify this difference.

The mechanism of BAC-induced bronchoconstriction is not clear. The main controversy is whether the dominant mode of action is IgE-dependent or non-IgE-dependent mediator release. A positive intradermal test result with BAC implies an IgE-mediated response, but BAC can elicit non-IgE mediated histamine release from rat mast cells and its bronchoconstriction can be blocked by antihistamines.

The bronchoconstrictive effects of BAC were originally described after inhalation of an ipratropium bromide nebulizer solution that contained 250 μg/mL BAC. Ipratropium is now only available as a preservative-free solution. Previously, a non-sterile, screwcap unit-dose albuterol nebulizer solution that contained 300 μg of BAC per 2.5 mg dose of albuterol was on the market, but it is no longer available.

Metered dose inhalers now contain no preservatives. A recently introduced propellant-free and multi-dose inhalation device, the Respimat® Soft Mist Inhaler™ (SMI), uses BAC and EDTA as preservatives. The amount of BAC delivered to the lungs in a single actuation is 0.44 μg, which is approximately 200 times lower than that delivered by wet nebulizer solutions. Patel et al reported that the decreases of FEV_1 in asthmatics with airway hyper-reactivity by four actuations of an aqueous placebo that contained no bronchodilator (12 μL water + 5.5 μg EDTA + 1.1 μg BAC/actuation) via Respimat® SMI were not different from decreases of FEV_1 by normal saline (−0.121 L vs. −0.094 L; 90% CI −0.107 to −0.052 L, within a pre-determined equivalence region of ±0.15 L).

In clinical practice in Korea, rapid-acting β_2-agonists for nebulization are available in sterile unit-dose screwcap vials and a nonsterile multidose dropper bottle (Ventolin® respiratory solution, GlaxoSmithKline, U.K.). The latter contains 50 μg BAC in each 2.5 mg dose of albuterol, and its manufacturer recommends using 2.5-5 mg of albuterol by nebulization in a proper clinical setting. According to GINA (Global Initiative for Asthma management and prevention) guidelines for hospital-based management of asthma exacerbation, rapid acting β_2-agonist, generally administered by nebulization, can be given at one dose every 20 minutes for 1 hour. Therefore, if a nonsterile multidose dropper bottle is used, inhalation of BAC 150–300 μg is possible over 1 hour.

In the present study, the median value of the % decrease of FEV_1 after inhalation of 600 μg BAC was 2.86% (range: −5.0 to 11.9). Thus, the currently available multi-dose dropper bottle albuterol is generally safe if used according to the recommended directions. However, for asthmatics with severe airway responsiveness, a paradoxical bronchoconstriction can occur at a relatively low BAC dose. In a clinical situation, if there is no response to a sufficient dose of BAC-containing bronchodilator solution or if dyspnea is paradoxically aggravated, BAC-induced bronchoconstriction should be considered. A bronchial provocation test with the actual dose of BAC included in currently-used nebulizer solutions to patients with more severe bronchial hyperresponsiveness will show more clinically meaningful results.

REFERENCES

1) Purohit A, Kopferschmitt-Kübler MC, Moreau C, Popin E, Blaumeiser M, Pauli G. Quaternary ammonium compounds and occupational asthma. Int Arch Occup Environ Health 73:423–427, 2000
2) Bernstein JA, Stauder T, Bernstein DI, Bernstein IL. A combined respiratory and cutaneous hypersensitivity syndrome induced by work exposure to quaternary amines. J Allergy Clin Immunol 94:257–259, 1994
3) Beasley CR, Rafferty P, Holgate ST. Bronchoconstrictor properties of preservatives in ipratropium bromide (Atrovent) nebuliser solution. Br Med J 294:1197–1198, 1987
4) Asmus MJ, Barros MD, Liang J, Chesrown SE, Hendelees L. Pulmonary function response to EDTA, an additive in nebulized bronchodilators. J Allergy Clin Immunol 107:68–72, 2001
5) Asmus MJ, Sherman J, Hendelees L. Bronchoconstrictor additives in bronchodilator solutions. J Allergy Clin Immunol 104:S53–S60, 1999
6) Zhang YG, Wright WJ, Tam WK, Nguyen-Dang TH, Salome CM, Woolcock AJ. Effect of inhaled preservatives on asthmatic subjects: ll. benzalkonium chloride. Am Rev Respir Dis 141:1405–1408, 1990
7) Boucher M, Roy MT, Henderson J. Possible association of benzalkonium chloride in nebulizer solutions with respiratory arrest. Ann Pharmacother 26:772–774, 1992
8) Beasley R, Burgess C, Holt S. Call for worldwide withdrawal of benzalkonium chloride from nebulizer solutions. J Allergy Clin Immunol 107:222–223, 2001
9) Read GW, Kiefer EF. Benzalkonium chloride: selective inhibitor of
histamine release induced by compound 48/80 and other polyamines. J Pharmacol Exp Ther 211:711-715, 1979
10) Kim SH, Ahn Y. Anaphylaxis caused by benzalkonium in a nebulizer solution. J Korean Med Sci 19:289-290, 2004
11) Miszkiel KA, Beasley R, Rafferty P, Holgate ST. The contribution of histamine release to bronchoconstriction provoked by inhaled benzalkonium chloride in asthma. Br J Clin Pharmacol 25:157-163, 1988
12) Patel KR, Pavia D, Lowe L, Spiteri M. Inhaled ethanolic and aqueous solutions via Respinhal Soft Mist Inhaler are well-tolerated in asthma patients. Respiration 73:434-440, 2006
13) Global Initiative for Asthma Management and Prevention. NHLBI/WHO workshop report. No. 95, p. 3659, National Bethesda, Institutes of Health. 1995